Editas Medicine, Inc.
EDIT- 1D
- -4.1%
Editas Medicine, Inc. in brief
Editas Medicine, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It was founded in 2013. Its market value was $363 M on 19 October 2026, which makes it the 13,968th largest listed company in the world and the 2,743rd largest in the USA on this site. In the year to December 2025 it had sales of $41 M and a net loss of $160 M. It employs about 264 people and Gilmore Neil O'Neill is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol EDIT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Editas Medicine, Inc.
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Editas Medicine, Inc. timeline
- 2013
- 🏁Founded
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2016
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 3 February 2016; shares registered for exchange trading on 29 January 2016.
- 2018
- •Legal Entity Identifier issuedLEI 5299000AON4Q9NT2JE42 registered.
- 2023
- 💰Record revenue of $78 millionFY2023, the highest of the 7 years on record.
Events of Editas Medicine, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,771 (Jan 2020) · #1,084 (Jan 2021) · #2,001 (Jan 2022) · #2,429 (Dec 2022) · #2,390 (Jul 2023) · #2,209 (Jan 2024) · #1,716 (Mar 2026) · #2,616 (Aug 2026) · #2,710 (Oct 2026) · #2,747 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 7.3×
- Price / book
- 13.3×
- Free cash flow yield
- -45.7%
- Net margin (TTM)
- -144.9%
- Operating margin
- -394.9%
- Return on equity
- -264.6%
- Liabilities / assets
- 85.4%
- Net debt
- $-93M
- Revenue growth
- +25.4%
- R&D / revenue
- 222.0%
- Revenue per employee
- $153 K
- Profit per employee
- $-606 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $41M | +25.4% | $-160M | $-160M | -395.0% |
| Dec 2024 | $32M | -58.6% | $-251M | $-237M | -733.8% |
| Dec 2023 | $78M | +296.3% | $-169M | $-153M | -196.1% |
| Dec 2022 | $20M | -22.8% | $-226M | $-220M | -1118.4% |
| Dec 2021 | $26M | — | $-193M | $-193M | -753.7% |
| Dec 2020 | — | — | $-135M | $-116M | — |
| Dec 2019 | $21M | -35.7% | $-141M | $-134M | -651.5% |
| Dec 2018 | $32M | — | $-114M | $-110M | -344.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-165M | $1M | $-166M | $-1.80 | — |
| Dec 2024 | $-210M | $9M | $-219M | $-2.88 | — |
| Dec 2023 | $-132M | $5M | $-137M | $-2.02 | — |
| Dec 2022 | $-177M | $4M | $-181M | $-3.21 | — |
| Dec 2021 | $-164M | $8M | $-172M | $-2.85 | — |
| Dec 2020 | $-180M | $7M | $-187M | $-1.98 | — |
| Dec 2019 | $-41M | $6M | $-47M | $-2.68 | — |
| Dec 2018 | $-46M | $5M | $-50M | $-2.33 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $10M (+37.4% on a year earlier), net income $-23M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Oct 8, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations · Directors or officers changed
- Jun 18, 20268-KCurrent reportShareholder vote
- May 26, 20268-KCurrent reportMaterial agreement · Other events
- May 26, 20268-KCurrent reportOther events
- May 26, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 14, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 5, 202610-QQuarterly report · period to Mar 2026
- May 5, 20268-KCurrent reportResults of operations
Official filings of Editas Medicine, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $41 M
- Operating income
- $-160 M
- Net income
- $-160 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $187 M
- Total liabilities
- $159 M
- Total equity
- $27 M
As of December-2025
Top 100 institutional investors in Editas Medicine, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 14,402,109 | +3,812,119 (+36.00%) | 9.33% | $37 M | Nov 13, 2026 |
| 2 | TCG Crossover Management, LLC | 11,111,111 | 0 (0.00%) | 7.20% | $29 M | Nov 16, 2026 |
| 3 | Ra Capital Management, L.P. | 8,889,000 | 0 (0.00%) | 5.76% | $23 M | Nov 16, 2026 |
| 4 | Commodore Capital LP | 8,889,000 | 0 (0.00%) | 5.76% | $23 M | Nov 16, 2026 |
| 5 | ADAR1 Capital Management, LLC | 8,889,000 | 0 (0.00%) | 5.76% | $23 M | Nov 16, 2026 |
| 6 | Paradigm Biocapital Advisors LP | 7,575,140 | +1,988,515 (+35.59%) | 4.91% | $19 M | Nov 16, 2026 |
| 7 | State Street Corp | 7,038,580 | +4,846,777 (+221.13%) | 4.56% | $18 M | Nov 12, 2026 |
| 8 | Vanguard Capital Management LLC | 6,073,405 | -67,931 (-1.11%) | 3.94% | $16 M | Nov 13, 2026 |
| 9 | Vanguard Portfolio Management LLC | 4,681,324 | +1,082,985 (+30.10%) | 3.03% | $12 M | Nov 13, 2026 |
| 10 | Geode Capital Management, LLC | 3,888,523 | +1,319,451 (+51.36%) | 2.52% | $10 M | Nov 6, 2026 |
| 11 | Woodline Partners LP | 3,555,497 | 0 (0.00%) | 2.30% | $9 M | Nov 16, 2026 |
| 12 | Vivo Capital, LLC | 3,555,250 | 0 (0.00%) | 2.30% | $9 M | Nov 13, 2026 |
| 13 | Opaleye Management Inc. | 3,486,452 | -375,478 (-9.72%) | 2.26% | $9 M | Nov 16, 2026 |
| 14 | Goldman Sachs Group Inc | 3,245,032 | +630,996 (+24.14%) | 2.10% | $8 M | Nov 16, 2026 |
| 15 | D. E. Shaw & Co., Inc. | 3,190,146 | +1,289,144 (+67.81%) | 2.07% | $8 M | Nov 16, 2026 |
| 16 | GordonMD Global Investments LP | 3,127,000 | 0 (0.00%) | 2.03% | $8 M | Nov 16, 2026 |
| 17 | Marshall Wace, LLP | 3,024,503 | +987,216 (+48.46%) | 1.96% | $8 M | Nov 13, 2026 |
| 18 | Renaissance Technologies LLC | 2,497,638 | +28,719 (+1.16%) | 1.62% | $6 M | Nov 12, 2026 |
| 19 | Logos Global Management LP | 2,222,000 | 0 (0.00%) | 1.44% | $6 M | Nov 16, 2026 |
| 20 | Seven Fleet Capital Management LP | 1,915,871 | +585,371 (+44.00%) | 1.24% | $5 M | Nov 16, 2026 |
| 21 | Jpmorgan Chase & Co | 1,866,640 | +4,146 (+0.22%) | 1.21% | $5 M | Nov 12, 2026 |
| 22 | UBS Group AG | 1,427,276 | +676,513 (+90.11%) | 0.92% | $4 M | Nov 10, 2026 |
| 23 | Two Sigma Investments, LP | 1,320,169 | -12,807 (-0.96%) | 0.86% | $3 M | Nov 16, 2026 |
| 24 | Raymond James Financial Inc | 1,317,272 | -1,675 (-0.13%) | 0.85% | $3 M | Nov 12, 2026 |
| 25 | Kennedy Capital Management LLC | 1,302,373 | +270,240 (+26.18%) | 0.84% | $3 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Charles Schwab Investment Management Inc | 1,241,002 | +372,970 (+42.97%) | 0.80% | $3 M | Nov 16, 2026 |
| 27 | Northern Trust Corp | 1,193,623 | +373,930 (+45.62%) | 0.77% | $3 M | Nov 16, 2026 |
| 28 | Ameriprise Financial Inc | 1,129,721 | New | 0.73% | $3 M | Nov 16, 2026 |
| 29 | HighVista Strategies LLC | 1,107,128 | New | 0.72% | $3 M | Nov 13, 2026 |
| 30 | Vanguard Fiduciary Trust Co | 984,633 | +241,683 (+32.53%) | 0.64% | $3 M | Nov 13, 2026 |
| 31 | AQR Capital Management LLC | 981,513 | -590,729 (-37.57%) | 0.64% | $3 M | Nov 16, 2026 |
| 32 | Nantahala Capital Management, LLC | 852,700 | -852,700 (-50.00%) | 0.55% | $2 M | Nov 13, 2026 |
| 33 | Acadian Asset Management LLC | 639,634 | -399,367 (-38.44%) | 0.41% | $2 M | Nov 9, 2026 |
| 34 | Los Angeles Capital Management LLC | 602,946 | +331,760 (+122.34%) | 0.39% | $2 M | Nov 12, 2026 |
| 35 | Nuveen, LLC | 550,797 | +29,584 (+5.68%) | 0.36% | $1 M | Nov 10, 2026 |
| 36 | Bank Of America Corp /de/ | 521,374 | +289,547 (+124.90%) | 0.34% | $1 M | Nov 16, 2026 |
| 37 | Point72 Asset Management, L.P. | 512,506 | +387,272 (+309.24%) | 0.33% | $1 M | Nov 16, 2026 |
| 38 | Barclays PLC | 510,903 | +361,639 (+242.28%) | 0.33% | $1 M | Nov 6, 2026 |
| 39 | Eversept Partners, LP | 456,923 | -1,886 (-0.41%) | 0.30% | $1 M | Nov 16, 2026 |
| 40 | Casdin Capital, LLC | 445,000 | 0 (0.00%) | 0.29% | $1 M | Nov 16, 2026 |
| 41 | Morgan Stanley | 436,277 | +94,112 (+27.50%) | 0.28% | $1 M | Nov 13, 2026 |
| 42 | Bank of New York Mellon Corp | 391,021 | +128,396 (+48.89%) | 0.25% | $1 M | Nov 5, 2026 |
| 43 | Wellington Management Group LLP | 365,035 | +55,640 (+17.98%) | 0.24% | $1 M | Nov 16, 2026 |
| 44 | Susquehanna Portfolio Strategies, LLC | 361,685 | -115,414 (-24.19%) | 0.23% | $1 M | Nov 16, 2026 |
| 45 | Invesco Ltd. | 279,477 | +67,597 (+31.90%) | 0.18% | $1 M | Nov 12, 2026 |
| 46 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 260,038 | +108,632 (+71.75%) | 0.17% | $1 M | Nov 16, 2026 |
| 47 | Susquehanna International Group, LLP | 253,937 | +161,092 (+173.51%) | 0.16% | $1 M | Nov 16, 2026 |
| 48 | LPL Financial LLC | 240,754 | +9,639 (+4.17%) | 0.16% | $1 M | Nov 6, 2026 |
| 49 | Quadrature Capital Ltd | 236,538 | New | 0.15% | $1 M | Nov 13, 2026 |
| 50 | Citadel Advisors LLC | 234,312 | +21,551 (+10.13%) | 0.15% | $1 M | Nov 16, 2026 |
| 51 | Gsa Capital Partners LLP | 231,772 | -135,375 (-36.87%) | 0.15% | $1 M | Nov 16, 2026 |
| 52 | Erste Asset Management GmbH | 230,000 | 0 (0.00%) | 0.15% | $1 M | Nov 12, 2026 |
| 53 | Millennium Management LLC | 211,484 | -287,513 (-57.62%) | 0.14% | $1 M | Nov 16, 2026 |
| 54 | Peak6 LLC | 197,144 | -218,297 (-52.55%) | 0.13% | $1 M | Nov 13, 2026 |
| 55 | Rafferty Asset Management, LLC | 183,590 | New | 0.12% | $0 M | Nov 13, 2026 |
| 56 | DAFNA Capital Management LLC | 180,470 | +10,000 (+5.87%) | 0.12% | $0 M | Nov 16, 2026 |
| 57 | Russell Investments Group, Ltd. | 177,786 | +27,922 (+18.63%) | 0.12% | $0 M | Nov 6, 2026 |
| 58 | Squarepoint Ops LLC | 177,198 | New | 0.11% | $0 M | Nov 9, 2026 |
| 59 | Price T Rowe Associates Inc /MD/ | 172,865 | +53,436 (+44.74%) | 0.11% | $0 M | Nov 16, 2026 |
| 60 | Cambridge Investment Research Advisors, Inc. | 161,244 | -162,512 (-50.20%) | 0.10% | $0 M | Nov 2, 2026 |
| 61 | Connor, Clark & Lunn Investment Management Ltd. | 158,357 | New | 0.10% | $0 M | Nov 10, 2026 |
| 62 | Alliancebernstein L.P. | 156,980 | -30,950 (-16.47%) | 0.10% | $0 M | Nov 16, 2026 |
| 63 | XTX Topco Ltd | 146,283 | +122,315 (+510.33%) | 0.09% | $0 M | Nov 16, 2026 |
| 64 | Rhumbline Advisers | 137,863 | +20,446 (+17.41%) | 0.09% | $0 M | Nov 10, 2026 |
| 65 | Deutsche Bank AG\ | 134,632 | +35,267 (+35.49%) | 0.09% | $0 M | Nov 6, 2026 |
| 66 | Ieq Capital, LLC | 126,083 | -91,702 (-42.11%) | 0.08% | $0 M | Nov 10, 2026 |
| 67 | Bridgeway Capital Management, LLC | 123,882 | -2,118 (-1.68%) | 0.08% | $0 M | Nov 16, 2026 |
| 68 | Empowered Funds, LLC | 123,882 | New | 0.08% | $0 M | Nov 13, 2026 |
| 69 | Mariner, LLC | 119,606 | -49,685 (-29.35%) | 0.08% | $0 M | Nov 12, 2026 |
| 70 | FMR LLC | 114,322 | +3,124 (+2.81%) | 0.07% | $0 M | Nov 10, 2026 |
| 71 | Canada Pension Plan Investment Board | 109,500 | +67,100 (+158.25%) | 0.07% | $0 M | Nov 16, 2026 |
| 72 | CANADA LIFE ASSURANCE Co | 106,586 | +27,984 (+35.60%) | 0.07% | $0 M | Nov 13, 2026 |
| 73 | MetLife Investment Management, LLC | 90,085 | +33,869 (+60.25%) | 0.06% | $0 M | Nov 16, 2026 |
| 74 | American Century Companies Inc | 84,482 | -8,114 (-8.76%) | 0.05% | $0 M | Nov 12, 2026 |
| 75 | Citigroup Inc | 80,886 | +18,922 (+30.54%) | 0.05% | $0 M | Nov 4, 2026 |
| 76 | Panagora Asset Management Inc | 77,969 | New | 0.05% | $0 M | Nov 12, 2026 |
| 77 | Wells Fargo & Company/mn | 73,325 | -47,428 (-39.28%) | 0.05% | $0 M | Nov 16, 2026 |
| 78 | Graham Capital Management, L.P. | 73,290 | +31,818 (+76.72%) | 0.05% | $0 M | Nov 16, 2026 |
| 79 | SEI Investments Co | 73,084 | +4,816 (+7.05%) | 0.05% | $0 M | Nov 10, 2026 |
| 80 | BNP Paribas Financial Markets | 72,378 | +50,393 (+229.22%) | 0.05% | $0 M | Nov 12, 2026 |
| 81 | Stifel Financial Corp | 72,338 | -2,444 (-3.27%) | 0.05% | $0 M | Nov 12, 2026 |
| 82 | Prudential Financial Inc | 70,750 | +52,010 (+277.53%) | 0.05% | $0 M | Nov 16, 2026 |
| 83 | Joel Isaacson & Co., LLC | 68,144 | 0 (0.00%) | 0.04% | $0 M | Nov 5, 2026 |
| 84 | Qube Research & Technologies Ltd | 65,959 | New | 0.04% | $0 M | Nov 13, 2026 |
| 85 | Profund Advisors LLC | 65,291 | New | 0.04% | $0 M | Oct 29, 2026 |
| 86 | China Universal Asset Management Co., Ltd. | 64,022 | +19,598 (+44.12%) | 0.04% | $0 M | Oct 28, 2026 |
| 87 | Group One Trading LLC | 58,831 | +8,482 (+16.85%) | 0.04% | $0 M | Nov 10, 2026 |
| 88 | MML Investors Services, LLC | 57,820 | +5,732 (+11.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 89 | Vanguard Global Advisers, LLC | 54,714 | +11,851 (+27.65%) | 0.04% | $0 M | Nov 13, 2026 |
| 90 | New York State Common Retirement Fund | 54,294 | +49,900 (+1135.64%) | 0.04% | $0 M | Nov 17, 2026 |
| 91 | Creative Planning | 49,412 | +3,840 (+8.43%) | 0.03% | $0 M | Nov 2, 2026 |
| 92 | Turner Financial Group, Inc. | 44,956 | New | 0.03% | $0 M | Nov 9, 2026 |
| 93 | Police & Firemen's Retirement System of New Jersey | 43,559 | +9,686 (+28.60%) | 0.03% | $0 M | Nov 9, 2026 |
| 94 | Brevan Howard Capital Management LP | 43,415 | +29,056 (+202.35%) | 0.03% | $0 M | Nov 16, 2026 |
| 95 | Osaic Holdings, Inc. | 43,386 | -26,738 (-38.13%) | 0.03% | $0 M | Nov 12, 2026 |
| 96 | EntryPoint Capital, LLC | 41,544 | +14,600 (+54.19%) | 0.03% | $0 M | Nov 13, 2026 |
| 97 | Manufacturers Life Insurance Company, The | 41,474 | +14,209 (+52.11%) | 0.03% | $0 M | Nov 13, 2026 |
| 98 | Vanguard Personalized Indexing Management, LLC | 40,850 | +2,545 (+6.64%) | 0.03% | $0 M | Nov 16, 2026 |
| 99 | Quinn Opportunity Partners LLC | 40,000 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 100 | Wealth Enhancement Advisory Services, LLC | 39,243 | -52,851 (-57.39%) | 0.03% | $0 M | Oct 13, 2026 |
Mutual funds holding Editas Medicine, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 4.89 M | $16 M | 3.2% | <0.01% | +62% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.64 M | $9 M | 1.7% | 0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc. | 2.03 M | $7 M | 1.3% | 0.05% | +8.5% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.10 M | $4 M | 0.71% | <0.01% | +2.2% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.09 M | $3 M | 0.71% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 844,017 | $3 M | 0.55% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 687,467 | $2 M | 0.45% | 0.02% | −6.0% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 509,394 | $2 M | 0.33% | <0.01% | +53% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 505,306 | $2 M | 0.33% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 476,309 | $2 M | 0.31% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 415,301 | $1 M | 0.27% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 336,592 | $1 M | 0.22% | 0.07% | +36% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 291,435 | $1 M | 0.19% | <0.01% | +7.8% | May 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 278,861 | $1 M | 0.18% | 0.07% | −5.7% | Jun 30, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 278,830 | $1 M | 0.18% | 0.08% | −6.7% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 269,751 | $1 M | 0.17% | 0.10% | +43% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 231,010 | $1 M | 0.15% | 0.02% | new | May 29, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 238,520 | $1 M | 0.15% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 243,722 | $1 M | 0.16% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 173,990 | $1 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 185,216 | $1 M | 0.12% | 0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 146,497 | $1 M | 0.09% | <0.01% | +5.2% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 126,000 | $0 M | 0.08% | 0.28% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 121,315 | $0 M | 0.08% | <0.01% | −86% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 111,550 | $0 M | 0.07% | 0.02% | +33% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 133,489 | $0 M | 0.09% | <0.01% | +20% | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 96,350 | $0 M | 0.06% | <0.01% | +1.5% | May 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 95,393 | $0 M | 0.06% | 0.03% | −38% | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 101,390 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 89,916 | $0 M | 0.06% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 119,007 | $0 M | 0.08% | 0.01% | +62% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 83,985 | $0 M | 0.05% | <0.01% | +50% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 83,965 | $0 M | 0.05% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 75,517 | $0 M | 0.05% | 0.02% | +14% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 66,134 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 68,596 | $0 M | 0.04% | 0.07% | −14% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 66,901 | $0 M | 0.04% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 62,920 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 62,222 | $0 M | 0.04% | 0.08% | −5.3% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 61,938 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 77,314 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 56,803 | $0 M | 0.04% | 0.08% | new | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 55,042 | $0 M | 0.04% | <0.01% | +74% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 53,398 | $0 M | 0.03% | <0.01% | +60% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 64,120 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 46,207 | $0 M | 0.03% | <0.01% | −8.9% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 43,300 | $0 M | 0.03% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 53,033 | $0 M | 0.03% | <0.01% | −4.5% | Jul 31, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 41,896 | $0 M | 0.03% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 40,956 | $0 M | 0.03% | 0.04% | −5.0% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 37,372 | $0 M | 0.02% | <0.01% | +7.3% | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 39,850 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION | 37,088 | $0 M | 0.02% | 0.05% | no change | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 47,823 | $0 M | 0.03% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 37,572 | $0 M | 0.02% | 0.09% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 44,179 | $0 M | 0.03% | 0.01% | +59% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 32,379 | $0 M | 0.02% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION | 31,251 | $0 M | 0.02% | 0.06% | no change | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 32,539 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 41,896 | $0 M | 0.03% | 0.06% | — | Mar 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 31,081 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 30,771 | $0 M | 0.02% | <0.01% | −4.3% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 27,860 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 34,800 | $0 M | 0.02% | <0.01% | +0.7% | Jul 31, 2026 |
| 🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust | 25,247 | $0 M | 0.02% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 24,946 | $0 M | 0.02% | <0.01% | −9.0% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 22,592 | $0 M | 0.01% | 0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 22,374 | $0 M | 0.01% | 0.03% | +26% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 21,319 | $0 M | 0.01% | 0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 18,768 | $0 M | 0.01% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 23,432 | $0 M | 0.02% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 17,575 | $0 M | 0.01% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 15,400 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 15,662 | $0 M | 0.01% | 0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 15,263 | $0 M | <0.01% | 0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 14,985 | $0 M | <0.01% | <0.01% | −88% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 14,825 | $0 M | <0.01% | 0.01% | +44% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 17,642 | $0 M | 0.01% | <0.01% | +58% | Jul 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 13,394 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 13,312 | $0 M | <0.01% | 0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC | 13,144 | $0 M | <0.01% | 0.03% | −9.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 14,750 | $0 M | <0.01% | <0.01% | +0.4% | Jul 31, 2026 |
| 🇺🇸 EQ/Common Stock Index PortfolioEquitable Investment Management Group, LLC | 11,500 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 9,793 | $0 M | <0.01% | <0.01% | +57% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 12,174 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 12,106 | $0 M | <0.01% | <0.01% | +28% | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 9,500 | $0 M | <0.01% | <0.01% | −34% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 8,245 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 8,247 | $0 M | <0.01% | 0.01% | −28% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 7,608 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 8,094 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 7,224 | $0 M | <0.01% | 0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 7,077 | $0 M | <0.01% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 6,990 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 7,754 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,650 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 5,280 | $0 M | <0.01% | <0.01% | −9.4% | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 6,257 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 4,633 | $0 M | <0.01% | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 4,715 | $0 M | <0.01% | 0.01% | −42% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Editas Medicine, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER | Sell10b5-1 plan | -7,814 | $2.416 | $19 K | 70,379 | Form 4 |
| filed | Gilmore Neil O'NeillCEO, Director | Sell10b5-1 plan | -21,164 | $2.416 | $51 K | 265,592 | Form 4 |
| filed | Gilmore Neil O'NeillCEO, Director | Grant or award | +43,567 | — | — | 286,756 | Form 4 |
| filed | Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER | Grant or award | +16,533 | — | — | 78,193 | Form 4 |
| filed | Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER | Sell10b5-1 plan | -709 | $3.040 | $2 K | 61,660 | Form 4 |
| filed | Gilmore Neil O'NeillCEO, Director | Sell10b5-1 plan | -5,124 | $3.040 | $16 K | 243,189 | Form 4 |
| filed | Amy ParisonSVP, Chief Financial Officer | Sell10b5-1 plan | -453 | $3.040 | $1 K | 13,839 | Form 4 |
| filed | Amy ParisonSVP, Chief Financial Officer | Sell10b5-1 plan | -678 | $2.580 | $2 K | 14,292 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Editas Medicine, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-2.6 reverse split
Trading halts
- 2026-05-26 13:30 UTC, code LUDP, resumed 13:35 UTC
Fails to deliver
- : 446 shares at $2.35
- : 85 shares at $2.45
- : 9,845 shares at $2.75
- : 301 shares at $2.69
- : 180 shares at $2.83
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Editas Medicine, Inc. scorecard#
Passes 7 of the 22 checks that could be worked out: strongest in growth (3 of 5), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 19, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median13.3×Price to book 13.3× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median7.3×Price to sales 7.3× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-45.7%Free cash flow is -45.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 5
- ✓Revenue grew in the newest year25.4%Revenue up 25.4% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years27.1%27.1% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median27.1%27.1% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.80 vs -2.88Diluted EPS -1.80 in fiscal 2025 against -2.88 the year before (report's currency).
- ✗Net income higher than five years earlier-$160 M-$160 M in fiscal 2025 against -$116 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 5
- ✗Profitable in the newest year-$160 MNet income -$160 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-394.9%-394.9% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-198.1%-198.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-394.9%-394.9% in fiscal 2025 against -1146.4% in 2022.
Financial health2 of 6
- ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.54 at the end of fiscal 2025.
- ✗Debt below equity2.0×Debt to equity 1.96 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $93 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-25.9×Operating income -25.9 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-12.71Z-score -12.71 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year7.8%Diluted shares up 7.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Editas Medicine, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -394.9% | -60.5% | |
| Net margin | -395.0% | -68.9% | |
| Return on equity | -198.1% | -61.0% | |
| Revenue growth, 3 years a year | 27.2% | 12.9% | |
| Revenue growth | 25.4% | 15.8% | |
| Debt to equity | 1.96× | 0.26× |
1of 8on the Piotroski tests of financial strength
- Net loss of $160 million, the 12th loss-making year in a row.
- Free cash flow was negative: -$166 million.
- The share count rose 7.8% in the year.
- Operating income covers the interest bill only -25.9 times.
Editas Medicine, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 41+25.4%100% | 32−58.6%100% | 78+296%100% | 20−22.8%100% | 26−71.8%100% | 91+342%100% | 21−35.7%100% | 32+133%100% | 14+127%100% | 6.1—100% | |
| Research and development | 90−54.9%222% | 199+12.2%617% | 178+1.5%227% | 175+22.8%888% | 143−9.8%558% | 158+63.1%174% | 97+6.9%472% | 91+9.0%284% | 83+45.9%606% | 57—941% | |
| General and administrative | 50−30.7%123% | 72+3.4%223% | 70−1.5%89.2% | 71−7.2%359% | 76+12.7%298% | 68+4.7%74.5% | 65+17.4%314% | 55+8.9%172% | 51+9.2%368% | 46—764% | |
| Operating expenses | 201−29.3%495% | 283+14.6%877% | 247+0.7%317% | 246+12.3%1246% | 219−3.1%856% | 226+39.7%249% | 161+10.8%786% | 146+9.0%456% | 134+29.5%974% | 103—1706% | |
| Operating income | −160—−395% | −251—−777% | −169—−217% | −226—−1146% | −193—−756% | −135—−149% | −141—−686% | −114—−356% | −120—−874% | −97—−1606% | |
| Interest expense and finance costs | 2.1—5.3% | 0r2.1—0.0% | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −0.1−100%−0.1% | 14−11.9%43.5% | 16+189%20.4% | 5.5+757%28.0% | 0.6−96.6%2.5% | 19+163%20.8% | 7.2+90.2%35.0% | 3.8—11.8% | −0.4−7920%−2.8% | 0.0—0.1% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Net income including minority interests | — | — | — | −220—−1118% | −193—−754% | −116—−128% | −134—−651% | −110—−344% | −120—−876% | −97—−1606% | |
| Net income attributable to shareholders | −160—−395% | −237—−734% | −153—−196% | −220—−1118% | −193—−754% | −116—−128% | −134—−651% | −110—−344% | −120—−876% | −97—−1606% | |
| Earnings per share, basic | -1.80—— | -2.88—— | -2.02—— | -3.21—— | -2.85—— | -1.98—— | -2.68—— | -2.33—— | -2.98—— | -3.02—— | |
| Earnings per share, diluted | -1.80—— | -2.88—— | -2.02—— | -3.21—— | -2.85r-2.83—— | -1.98—— | -2.68—— | -2.33—— | -2.98—— | -3.02—— | |
| Shares, weighted average (basic) | 89+7.8%— | 82+8.4%— | 76+10.6%— | 69+1.5%— | 68+15.4%— | 59+17.3%— | 50—— | — | — | — | |
| Shares, weighted average (diluted) | 89+7.8%— | 82+8.4%— | 76+10.6%— | 69+1.5%— | 68+15.4%— | 59+17.3%— | 50+6.1%— | 47+16.8%— | 40+25.2%— | 32—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 147+11.5%78.6% | 132+6.4%38.5% | 124−12.6%24.8% | 142r142−30.5%27.5% | 204+45.7%30.0% | 140−41.4%24.4% | 238+76.7%46.8% | 135−8.1%32.1% | 147−20.9%39.3% | 185—80.9% | |
| Short-term investments | 0−100%0.0% | 138−30.6%40.5% | 199−1.6%40.0% | 203−31.6%39.4% | 296+12.9%43.7% | 262+19.9%45.8% | 219−6.5%43.0% | 234+28.3%55.7% | 183—48.9% | — | |
| Receivables | 15−6.7%8.1% | 16+59.7%4.8% | 10+98.0%2.0% | 5.1+1827%1.0% | 0.3−95.6%0.0% | 6.0+1347%1.1% | 0.4+1293%0.1% | 0.0−95.6%0.0% | 0.7+672%0.2% | 0.1—0.0% | |
| Other current assets | 2.1−33.9%1.1% | 3.1−58.4%0.9% | 7.5+2.7%1.5% | 7.3+1.9%1.4% | 7.2−34.1%1.1% | 11+73.9%1.9% | 6.3+8.5%1.2% | 5.8+143%1.4% | 2.4+34.4%0.6% | 1.8—0.8% | |
| Current assets | 164−43.4%87.9% | 289−15.1%84.7% | 341−4.5%68.3% | 357−29.7%69.4% | 507+21.1%74.9% | 419−9.6%73.2% | 464+23.8%91.1% | 375+12.8%89.2% | 332+77.5%89.0% | 187—81.7% | |
| Property, plant and equipment | 3.5−75.6%1.9% | 14+20.5%4.2% | 12−22.7%2.4% | 16−9.0%3.0% | 17+22.1%2.5% | 14+28.8%2.4% | 11−72.9%2.1% | 40+2.0%9.6% | 39−2.3%10.6% | 40—17.6% | |
| Right-of-use (leased) assets | 16−50.5%8.6% | 33−3.3%9.5% | 34−22.8%6.7% | 44+66.8%8.5% | 26+4.2%3.9% | 25−12.6%4.4% | 29—5.7% | — | — | — | |
| Total assets | 187−45.4%100% | 342−31.6%100% | 499−2.9%100% | 514−24.1%100% | 677+18.3%100% | 573+12.5%100% | 509+21.1%100% | 420+12.6%100% | 373+62.9%100% | 229—100% | |
| Accounts payable | 2.6−52.6%1.4% | 5.5−33.6%1.6% | 8.3−13.1%1.7% | 9.5+88.3%1.8% | 5.1−21.2%0.7% | 6.4+9.7%1.1% | 5.8+9.7%1.1% | 5.3+32.5%1.3% | 4.0−13.4%1.1% | 4.6—2.0% | |
| Debt due within a year | 5.00.0%2.7% | 5.0—1.5% | 0—0.0% | — | — | — | — | — | — | — | |
| Current liabilities | 46−40.1%24.8% | 77+22.2%22.6% | 63+5.2%12.7% | 60+28.2%11.7% | 47−19.5%6.9% | 58−2.9%10.2% | 60+67.0%11.8% | 36−2.2%8.5% | 37+11.0%9.8% | 33—14.4% | |
| Long-term debt | 54+2.2%28.7% | 52—15.4% | 0—0.0% | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 12−40.8%6.5% | 20−16.4%6.0% | 24−25.8%4.9% | 33+105%6.4% | 16−16.8%2.4% | 19−17.0%3.4% | 23—4.6% | — | — | — | |
| Total liabilities | 159−23.2%85.4% | 207+38.2%60.7% | 150−2.3%30.1% | 154+24.1%29.9% | 124−30.8%18.3% | 179−27.4%31.3% | 246+33.8%48.4% | 184+11.5%43.8% | 165+74.7%44.3% | 95—41.3% | |
| Retained earnings | −1,629—−873% | −1,468—−430% | −1,231—−247% | −1,078—−210% | −858—−127% | −665—−116% | −549—−108% | −416—−99.0% | −306—−81.9% | −186—−81.0% | |
| Shareholders' equity | 27−79.7%14.6% | 134−61.5%39.3% | 349−3.2%69.9% | 361−34.9%70.1% | 554+40.7%81.7% | 394+50.0%68.7% | 262+11.1%51.6% | 236+13.5%56.2% | 208+54.6%55.7% | 135—58.7% | |
| Total liabilities and equity | 187−45.4%100% | 342−31.6%100% | 499−2.9%100% | 514−24.1%100% | 677+18.3%100% | 573+12.5%100% | 509+21.1%100% | 420+12.6%100% | 373+62.9%100% | 229—100% | |
| Shares outstanding | 98+18.3%— | 83+1.2%— | 82+18.8%— | 69+0.6%— | 68+9.4%— | 63+15.1%— | 54+11.5%— | 49+9.6%— | 45+24.3%— | 36—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 10−53.3%24.7% | 21+8.2%66.3% | 20−32.4%25.3% | 29−32.5%149% | 43+87.4%170% | 23−15.0%25.5% | 27+2.4%133% | 27+13.8%83.3% | 23+38.4%170% | 17—279% | |
| Cash from operating activities | −165—−408% | −210—−651% | −132—−169% | −177—−900% | −164—−641% | −180—−198% | −41—−198% | −46—−143% | −9.4—−68.6% | −50r−50—−830% | |
| Capital expenditure | −0.6—−1.5% | −8.8—−27.3% | −4.7—−6.0% | −4.1—−20.9% | −8.0—−31.2% | −7.2—−7.9% | −6.2—−30.0% | −4.8—−14.9% | −2.1—−15.0% | −3.5—−57.7% | |
| Cash from investing activities | 139−14.5%342% | 162—502% | −3.7−103%−4.8% | 114—579% | −54—−213% | −141−1247%−155% | 12—59.7% | −53—−166% | −184—−1339% | −3.5r−5.1—−57.4% | |
| Debt issued | — | 57—176% | — | — | — | — | — | — | — | — | |
| Debt repaid | −2.9—−7.1% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Shares issued | 43—106% | 0−100%0.0% | 117—150% | 0−100%0.0% | 249+22.4%977% | 204+75.1%225% | 116+51.5%567% | 77−50.2%240% | 154+58.1%1123% | 97—1611% | |
| Cash from financing activities | 40−27.8%99.9% | 56−52.5%173% | 118+9093%151% | 1.3−99.5%6.5% | 282+25.9%1104% | 224+70.0%247% | 132+51.6%642% | 87−43.7%272% | 155+59.0%1126% | 97—1605% | |
| Change in cash | 14+76.2%34.3% | 7.9—24.4% | −18—−22.9% | −62−197%−315% | 64—250% | −96−193%−106% | 103—504% | −12—−37.1% | −39−189%−282% | 43r42—718% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 50+7.4%100% | 10+37.4%100% | 12+232%100% | 2.8−39.2%100% | 25*−19.2%100% | 7.5+12266%100% | 3.6+597%100% | 4.7+310%100% | 31*−49.0%100% | 0.1—100% | 0.5—100% | 1.1—100% | 60*—100% | |
| Research and development | 86−22.3%173% | 21+7.1%204% | 20+24.7%170% | 18−33.8%622% | 27*−43.6%111% | 20−58.5%262% | 16−70.2%452% | 27−45.5%571% | 49*−30.1%159% | 48—78097% | 54—10567% | 49—4298% | 70*—116% | |
| General and administrative | 47−15.0%93.7% | 13+9.4%130% | 12−9.8%97.6% | 10−23.5%361% | 11*−30.6%45.9% | 12−31.9%163% | 13−29.4%359% | 13−30.8%287% | 16*+13.1%53.4% | 18—29652% | 18—3549% | 19—1704% | 14*—24.1% | |
| Operating expenses | 125−48.9%252% | 35+8.0%334% | 30−44.8%256% | 28−65.6%983% | 32*−57.9%131% | 32−51.2%425% | 55−23.9%1541% | 81+18.6%1735% | 77*−8.1%252% | 66—107749% | 72—14116% | 68—6002% | 84*—140% | |
| Operating income | −76—−152% | −24—−234% | −19—−156% | −25—−883% | −7.8*—−31.3% | −25—−325% | −52—−1441% | −76—−1635% | −47*—−152% | −66—−107649% | −72—−14016% | −67—−5902% | −24*—−39.9% | |
| Interest expense and finance costs | 7.1−18.2%14.3% | 1.1−54.9%10.4% | 1.1−47.5%8.9% | 5.0+135%177% | 0*−100%0.0% | 2.4—31.8% | 2.0—56.5% | 2.1r2.2—45.7% | 2.2r2.1*—7.2% | 0—0.0% | 0—0.0% | 0—0.0% | — | |
| Other non-operating income (expense) | 3.4—6.8% | 0.9—8.6% | 0.3—2.7% | 0.0−72.0%0.7% | 2.1*+78.2%8.6% | −0.6−116%−7.5% | −1.7−139%−47.3% | 0.1−98.5%1.6% | 1.2*−76.5%3.9% | 3.5—5779% | 4.3—837% | 5.0—444% | 5.1*—8.5% | |
| Net income attributable to shareholders | −72—−145% | −23—−226% | −18—−153% | −25—−882% | −5.6*—−22.7% | −25—−333% | −53—−1488% | −76—−1633% | −45*—−148% | −62—−101870% | −68—−13179% | −62—−5458% | −19*—−31.4% | |
| Earnings per share, basic | — | -0.15—— | -0.15—— | -0.26—— | — | -0.28—— | -0.63—— | -0.92—— | — | -0.75—— | -0.82—— | -0.76—— | — | |
| Earnings per share, diluted | — | -0.15—— | -0.15—— | -0.26—— | — | -0.28—— | -0.63—— | -0.92—— | — | -0.75—— | -0.82—— | -0.76—— | — | |
| Shares, weighted average (basic) | 154+70.5%— | 154+70.5%— | 119+41.3%— | 98+17.8%— | — | 90+9.2%— | 84+2.6%— | 83+1.4%— | — | 82—— | 82—— | 82—— | — | |
| Shares, weighted average (diluted) | 154+70.5%— | 154+70.5%— | 119+41.3%— | 98+17.8%— | — | 90+9.2%— | 84+2.6%— | 83+1.4%— | — | 82—— | 82—— | 82—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 93—42.5% | 93−43.8%42.5% | 182+31.2%76.6% | 124−10.8%82.8% | 147+11.5%78.6% | 166+72.9%82.1% | 139+115%65.8% | 139+100%52.6% | 132+6.4%38.5% | 96—29.3% | 64—16.7% | 69—15.7% | 124—24.8% | |
| Short-term investments | 97—44.2% | 97—44.2% | 30−25.3%12.6% | — | 0−100%0.0% | 0−100%0.0% | 40−81.4%19.0% | 82−63.7%31.2% | 138−30.6%40.5% | 169—51.7% | 215—55.8% | 227—51.5% | 199—40.0% | |
| Receivables | 7.7—3.5% | 7.7−5.0%3.5% | 2.7+363%1.1% | 2.6+408%1.7% | 15−6.7%8.1% | 8.1+6352%4.0% | 0.6+141%0.3% | 0.5+108%0.2% | 16+59.7%4.8% | 0.1—0.0% | 0.2—0.1% | 0.2—0.1% | 10—2.0% | |
| Other current assets | 4.0—1.8% | 4.0+30.0%1.8% | 3.7−0.3%1.6% | 1.8−45.8%1.2% | 2.1−33.9%1.1% | 3.1−47.5%1.5% | 3.7−47.0%1.8% | 3.4−63.1%1.3% | 3.1−58.4%0.9% | 5.9—1.8% | 7.0—1.8% | 9.1—2.1% | 7.5—1.5% | |
| Current assets | 202—92.1% | 202+14.2%92.1% | 218+19.3%91.9% | 128−43.0%85.8% | 164−43.4%87.9% | 177−34.8%87.7% | 183−36.2%86.8% | 225−26.4%85.3% | 289−15.1%84.7% | 271—82.8% | 286—74.4% | 306—69.4% | 341—68.3% | |
| Property, plant and equipment | 2.2—1.0% | 2.2−48.9%1.0% | 2.6−43.8%1.1% | 2.9−64.8%1.9% | 3.5−75.6%1.9% | 4.3−72.2%2.1% | 4.6−67.7%2.2% | 8.2−38.3%3.1% | 14+20.5%4.2% | 15—4.7% | 14—3.7% | 13—3.0% | 12—2.4% | |
| Right-of-use (leased) assets | 12—5.6% | 12−30.2%5.6% | 14−27.7%5.8% | 15−41.7%10.3% | 16−50.5%8.6% | 18−50.8%8.7% | 19−48.6%9.0% | 26−15.9%10.0% | 33−3.3%9.5% | 36—10.9% | 37—9.6% | 31—7.1% | 34—6.7% | |
| Total assets | 219—100% | 219+8.8%100% | 237+12.7%100% | 149−43.4%100% | 187−45.4%100% | 202−38.4%100% | 211−45.3%100% | 264−40.1%100% | 342−31.6%100% | 328—100% | 385—100% | 440—100% | 499—100% | |
| Accounts payable | 6.8—3.1% | 6.8+116%3.1% | 4.7−29.5%2.0% | 4.3−20.7%2.9% | 2.6−52.6%1.4% | 3.2−74.7%1.6% | 6.7−51.2%3.2% | 5.5−31.4%2.1% | 5.5−33.6%1.6% | 12—3.8% | 14—3.6% | 8.0—1.8% | 8.3—1.7% | |
| Debt due within a year | 7.5—3.4% | 7.5+50.0%3.4% | 7.5+50.0%3.2% | 7.5+50.0%5.0% | 5.00.0%2.7% | 5.0—2.5% | 5.0—2.4% | 5.0—1.9% | 5.0—1.5% | — | — | — | 0—0.0% | |
| Current liabilities | 72—32.6% | 72+15.9%32.6% | 68+3.8%28.8% | 40−45.6%26.6% | 46−40.1%24.8% | 62−14.6%30.6% | 66−11.3%31.3% | 73+10.0%27.7% | 77+22.2%22.6% | 72—22.1% | 74—19.3% | 66—15.1% | 63—12.7% | |
| Long-term debt | 49—22.5% | 49−8.8%22.5% | 48−6.6%20.3% | 47−4.8%31.6% | 54+2.2%28.7% | 54—26.8% | 52—24.5% | 50—18.8% | 52—15.4% | — | — | — | 0—0.0% | |
| Lease liabilities (non-current) | 7.4—3.4% | 7.4−45.2%3.4% | 9.0−40.0%3.8% | 11−41.0%7.1% | 12−40.8%6.5% | 14−38.6%6.7% | 15−26.9%7.1% | 18−17.5%6.8% | 20−16.4%6.0% | 22—6.7% | 21—5.3% | 22—4.9% | 24—4.9% | |
| Total liabilities | 135—61.5% | 135−28.4%61.5% | 132−31.0%55.6% | 145−28.0%97.0% | 159−23.2%85.4% | 188+23.9%93.3% | 191+25.3%90.9% | 201+37.9%76.3% | 207+38.2%60.7% | 152—46.4% | 153—39.7% | 146—33.1% | 150—30.1% | |
| Retained earnings | −1,695—−773% | −1,695—−773% | −1,672—−704% | −1,653—−1107% | −1,629—−873% | −1,623—−804% | −1,598—−759% | −1,545—−586% | −1,468—−430% | −1,423—−434% | −1,361—−354% | −1,293—−294% | −1,231—−247% | |
| Shareholders' equity | 85—38.5% | 85+528%38.5% | 105+449%44.4% | 4.4−92.9%3.0% | 27−79.7%14.6% | 13−92.3%6.7% | 19−91.7%9.1% | 62−78.8%23.7% | 134−61.5%39.3% | 176—53.6% | 232—60.3% | 294—66.9% | 349—69.9% | |
| Total liabilities and equity | 219—100% | 219+8.8%100% | 237+12.7%100% | 149−43.4%100% | 187−45.4%100% | 202−38.4%100% | 211−45.3%100% | 264−40.1%100% | 342−31.6%100% | 328—100% | 385—100% | 440—100% | 499—100% | |
| Shares outstanding | 98—— | 98+4.9%— | 98+12.0%— | 98+16.9%— | 98+18.3%— | 93+13.0%— | 87+6.0%— | 84+1.8%— | 83+1.2%— | 83—— | 82—— | 82—— | 82—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 9.0−24.4%18.1% | 2.6+15.4%24.8% | 2.2−17.7%18.4% | 2.1−29.4%74.2% | 2.1*−47.0%8.6% | 2.2−53.6%29.5% | 2.7−46.8%74.5% | 3.0−60.7%64.0% | 4.0*−24.8%13.1% | 4.8—7872% | 5.0—977% | 7.6—668% | 5.3*—8.9% | |
| Cash from operating activities | −110—−221% | −21*—−204% | −30*—−249% | −23—−815% | −36*—−147% | −31*—−409% | −50*—−1403% | −48—−1026% | −51*—−166% | −53*—−86210% | −57*—−11123% | −50—−4394% | −22*—−37.0% | |
| Capital expenditure | −0.3—−0.5% | 0*—0.0% | −0.1*—−0.9% | −0.1—−3.2% | −0.1*—−0.2% | −0.4*—−5.7% | 0*—0.0% | −0.1—−2.4% | −0.5*—−1.8% | −2.9*—−4789% | −3.5*—−681% | −1.9—−165% | −1.3*—−2.2% | |
| Cash from investing activities | −97−157%−194% | −67*−269%−646% | −30*−170%−251% | 0.1−99.9%2.3% | 0.1*−99.8%0.2% | 40*−52.9%525% | 43*−17.9%1192% | 56—1211% | 31*−50.7%101% | 84*—137670% | 52*—10127% | −4.7—−418% | 63*—105% | |
| Debt repaid | 0—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −2.9—−61.7% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | — | |
| Shares issued | 134+420%269% | −0.6*−104%−6.0% | 117*+1536%988% | 0−100%0.0% | 17*—69.0% | 17*—227% | 7.2*—201% | 1.4—30.8% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Cash from financing activities | 134+70.9%270% | −0.5*−103%−4.5% | 118*+1486%989% | 0—0.0% | 17*−68.8%70.0% | 17*—228% | 7.4*+2202%207% | −1.4−848%−30.9% | 56*+10700%181% | 0*—0.0% | 0.3*—62.8% | 0.2—16.9% | 0.5*—0.9% | |
| Change in cash | −72−206%−145% | −89*−442%−855% | 58*—489% | −23−422%−812% | −19*−153%−76.8% | 26*−17.5%343% | −0.2*—−4.2% | 7.2—154% | 36*−13.1%117% | 31*—51461% | −4.8*—−933% | −54—−4795% | 41*—68.5% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Editas Medicine, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$41 M100%+25%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Editas Medicine, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Gilmore Neil O'Neill | $2.4 M | $3.1 M | $999 K | $23 |
| 2024Gilmore Neil O'Neill | $5.1 M | −$3.1 M | $1.3 M | $14 |
| 2023Gilmore Neil O'Neill | $2.4 M | $3.8 M | $1.6 M | $114 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Editas Medicine, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Restructuring 1 · Directors and officers 5 · Material agreement 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2015 | $120 M | No. 1 | $50 to $250 million | 43 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Editas Medicine, Inc.#
$60 K spent on lobbying the US Congress and federal agencies in 2020, most often on health issues and medicare/medicaid.
- Health Issues2 reports
- Medicare/Medicaid2 reports
Lobbying firms hired in 2020
The Nickles Group, LLC $60 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2020 | $60 K | — | 2 |
| 2019 | $200 K | — | 4 |
| 2018 | $180 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Editas Medicine”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Editas Medicine, Inc.#
3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $117 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Scientist, Delivery Technology [00109010]Molecular and Cellular Biologists | 1 | $95 K |
| Scientist I, Assay Development in vitro/in vivo PharmacologyMolecular and Cellular Biologists | 1 | $135 K |
| Senior Associate Scientist [00114286]Molecular and Cellular Biologists | 1 | $117 K |
Where: Cambridge, MA 3
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 3 | 3 | $117 K | 3 |
| FY2025 | 5 | 5 | $102 K | 5 |
| FY2024 | 17 | 17 | $111 K | 19 |
| FY2023 | 5 | 5 | $110 K | 5 |
| FY2022 | 8 | 8 | $78 K | 8 |
| FY2021 | 9 | 9 | $108 K | 9 |
| FY2020 | 16 | 16 | $68 K | 16 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as EDITAS MEDICINE, INC.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | 180 | 180 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 180 people | Restructuring planSEC 8-K | “In connection with the Discontinuation, the Board approved a reduction in the Company’s employee workforce by approximately 180 positions, or approximately 65% (the “Reduction”).” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Editas Medicine, Inc. compares in Biotechnology
- Market cap$363 M · higher than 54% of 726
- Revenue$41 M · higher than 57% of 647
- Net margin-144.9% · higher than 35% of 408
- Revenue growth25.4% · higher than 65% of 438
- Price / sales7.3× · lower than 53% of 339
- Price / book13.3× · lower than 12% of 534
- FCF yield-45.7% · higher than 26% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Editas Medicine, Inc.🇺🇸 | $363 M | — | -144.9% | +25.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 19, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Editas Medicine, Inc.? Verify and update this profile — free
Show Editas Medicine, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.